Policy & Regulation
Teva reports new ecopipam data showing tic reduction in Tourette syndrome
2 October 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), which develops medicines across neuroscience and immunology, on Friday released new anal...
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
2 October 2026 - US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and ado...
Clear Scientific reports positive CS-1103 Phase 2 Results in removing fentanyl from the Body
2 October 2026 - Clear Scientific, Inc., a US-based biopharmaceutical company, on Thursday announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that is c...
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
2 October 2026 - Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new pu...
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
1 October 2026 - Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceuti...
Pfizer's tilrekimig shows significant skin clearance in Phase 2 atopic dermatitis study
1 October 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday reported positive Phase 2 results for investigational tilrekimig (PF-07275315) in adults with moderate-to-severe atopic ...